Costa Mesa-based early stage venture capital investor CerraCap Ventures has scored an exit out of its portfolio, saying today that one of its companies, Totient, has been acquired by Absci. Financial details of the acquisition were not announced. CerraCap Ventures said it made its investment in Totient out of its second fund, CerraCap II LP. The venture investor says the exit is the second for tht fund. Totient was developing a drug discovery platform which used human immune responses to identify novel antibodies and their therapeutic targets. CerraCap Ventures is led by founder and CEO Saurabh Ranjan.